Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole vs Risperidone in Schizophrenia
NCT00202007Phase 2Completed
- Sponsor
- Otsuka Holdings
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aripiprazole in schizophrenia (2 arms), sponsored by Otsuka Holdings. Primary endpoint: Deduction rate of Positive and Negative Syndrome Scale total score at 6 weeks. Started Feb 2005; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00202007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202007.